Articles tagged with: Thalomid
Results from a recently completed Phase 3 trial suggest that thalidomide may delay disease progression in patients with smoldering myeloma.
Specifically, patients in the trial who received thalidomide in combination with Zometa had a noticeably longer time to disease progression than patients who received Zometa alone.
Over a third of the patients who received thalidomide and Zometa also showed a tumor response, whereas none of the patients treated with Zometa alone had such a response.
However, more patients who received the thalidomide- Zometa combination experienced peripheral neuropathy (pain, tingling, or …
Results from a Spanish Phase 3 clinical trial suggest that initial treatment with a combination of Velcade, thalidomide, and dexamethasone may lead to better responses before and after stem cell transplantation, as compared to treatment with thalidomide and dexamethasone alone. In addition, treatment with the three-drug combination increases progression-free survival time.
The study investigators concluded that their findings support the use of a combination of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), often referred to as VTD, as initial treatment in newly diagnosed myeloma patients who are …
Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus prednisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.
In addition, elderly myeloma patients who receive Velcade plus thalidomide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus prednisone as maintenance therapy.
“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the differences didn’t …
The results of a recent Greek study indicate that kidney impairment is highly reversible in newly diagnosed multiple myeloma patients treated with regimens containing Velcade, thalidomide, and Revlimid.
Additionally, the Greek researchers found that Velcade (bortezomib)-based treatments were associated with a shorter time to response and higher rates of restoration of kidney function than thalidomide (Thalomid)- and Revlimid (lenalidomide)-based regimens.
Based on their findings, the researchers recommend that Velcade be used as initial therapy for myeloma patients with kidney impairment.
Dr. Baldeep Wirk of the University of …
Dr. Michel Attal from the Purpan Hospital in Toulouse, France, presented a review of current maintenance therapies for multiple myeloma during the American Society of Clinical Oncology (ASCO) annual meeting last month.
The focus of Dr. Attal’s presentation was on whether there is evidence to support the use of the novel anti-myeloma agents thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib) as maintenance therapy after initial therapy and stem cell transplantation.
Maintenance therapy refers to a prolonged, and often low-dose, form of treatment given to myeloma patients after …